It is anticipated that Bob will advise the company on the continued development and commercialisation of its Theta 3D sequencer.

Bob brings with him vast experience from his role at Illumina from 1999 to 2014, during which he helped the company to grow from a 30-employee startup to a much larger company bringing in more than $1.5bn in annual revenues.

Johan Strömqvist, Single Technologies’ chief executive officer, commented: “We are delighted to have Bob Kain join our board of advisors. Not only is it a huge vote of confidence in us and our technology, but also a vote of confidence in the future of sequencing.”

Discussing the company’s 3D sequencing, Bob added: “It is the first truly disruptive architecture I have seen that has the ability to reach the $10 per genome price point.”